Overview
Nurix Therapeutics is a clinical-stage biopharmaceutical leader specializing in the targeted modulation of protein levels through the ubiquitin-proteasome system. By 2026, their proprietary DELIGASE platform has evolved into a highly automated, AI-augmented engine for discovering small molecules that either degrade or stabilize specific proteins. The platform utilizes massive DNA-encoded libraries (DEL) combined with machine learning to predict ligand-protein binding interactions with unprecedented precision. This technical architecture allows Nurix to target 'undruggable' proteins—those lacking traditional active sites—by recruiting E3 ligases to trigger natural cellular degradation. Their market position is defined by a hybrid model of internal drug development and high-value strategic partnerships with giants like Gilead and Sanofi. Technically, the 2026 iteration of the platform integrates structural biology, computational chemistry, and high-throughput screening data into a unified predictive model, significantly reducing the 'hit-to-lead' timeline in oncology and autoimmune therapeutic discovery.